LARIMAR THERAPEUTICS, INC. Total Long-Term Debt
LARIMAR THERAPEUTICS, INC. (LRMR) had Total Long-Term Debt of $14.54 million as of 2019-12-31, per its 10-K filed 2020-03-05.
Discontinued › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:LongTermDebt · last filed 2020-03-05
- 2019-12-31: Long-term Debt $14.54M.
- 2019-09-30: Long-term Debt $16.36M.
- 2019-06-30: Long-term Debt $18.18M.
- 2019-03-31: Long-term Debt $20.00M.
| Period end | Long-term Debt |
|---|---|
| 2019-12-31 | $14.54M 10-K · filed 2020-03-05 |
| 2019-09-30 | $16.36M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $18.18M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $20.00M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $20.00M 10-K · filed 2019-03-14 |
| 2018-09-30 | $20.00M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $20.00M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $20.00M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $20.00M 10-Q · filed 2018-11-09 |
| 2016-12-31 | $3.18M 10-K · filed 2017-03-10 |
| 2016-09-30 | $3.94M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $4.68M 10-Q · filed 2016-08-05 |
| 2016-03-31 | $5.41M 10-Q · filed 2016-05-10 |
| 2015-09-30 | $6.82M 10-Q · filed 2015-11-13 |
| 2015-06-30 | $7.50M 10-Q · filed 2015-08-14 |
| 2015-03-31 | $7.50M 10-Q · filed 2015-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |